| Ticker |
TLSI
|
| CIK | 0001826667 |
| SIC | 3841 |
| Sector | Manufacturing |
| Industry Category | Medical Equipment |
| Industry Group | Surgical, Medical, And Dental Instruments And Supplies |
| Address | 6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031 |
| Website | trisaluslifesci.com |
| Phone | 415 336 8917 |
| CEO | Mary T. Szela |
| Employees | 106 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
TriSalus Life Sciences Inc (TLSI) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ...TriSalus Life Sciences Inc (TLSI) reports a 52% sales increase and successful product launches, while navigating increased expenses and strategic investments. TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue EstimatesTriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -22.73% and +5.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 GuidanceDENVER, August 12, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization TechniqueWESTMINSTER, Colo., August 11, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympto TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceWESTMINSTER, Colo., July 30, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 9:00 a.m. ET. Management will also host investor meetings during |
